Table 1.

Demographics, risk factors, and pertinent medications in all patients (N = 60) and in those separated by initial cognitive screening scores. Data include mean/standard deviation for continuous measures and frequency/percentages for categorical measures

Characteristic	All participants (n = 60)				MoCA < 26 (n = 23)				MoCA ≥ 26 (n = 29)				P †
	Min	Max	Mean	SD	Min	Max	Mean	SD	Min	Max	Mean	SD
Age (years)	50	86	64	7.1	51	86	65.3	7.3	50	75	63.3	7.3	0.31
	Count			%	Count			%	Count			%
Male gender	54			90	23			100	24			83	0.059*
Education													0.40**
< High school	3			5	2			9	0			0
High school	16			27	5			22	8			28
Some college	28			47	12			52	14			48
College/advanced degree	13			22	4			17	7			24
Smoking status													0.084
Never	13			22	6			26	4			14
Former	22			36	5			22	15			52
Current	25			42	12			52	10			34
Medication
Antiplatelets	43			72	18			78	19			66	0.31
Statins	46			77	19			83	23			79	> 0.9*
ACE inhibitor	28			47	8			35	17			59	0.09
ARBs	7			12	3			13	3			10	> 0.9*
Beta blocker	32			53	15			65	13			45	0.14
Calcium channel blocker	22			36	10			43	11			38	0.69
Diuretic	25			42	12			52	11			38	0.30
Comorbidities
Coronary artery disease	20			34	7			30	10			36	0.69
Atrial fibrillation	1			2	0			0	0			0	–
Peripheral artery disease	6			10	2			9	2			7	> 0.9*
Hypercholesterolemia	53			88	21			91	25			86	0.68*
Hypertension	55			92	22			96	25			86	0.37*
Diabetes	28			47	10			43	13			45	0.92

ACE inhibitor angiotensin-converting enzyme inhibitor, ARBs angiotensin II receptor blockers

†P value reflects comparison of means, using a two-sample t test, for continuous measures and a comparison of proportions, using a chi-square test, for categorical measures, unless otherwise indicated, between groups defined by initial cognitive screening scores

*Fisher’s exact test

**Cochran-Armitage trend test